Showing 4461-4470 of 5910 results for "".
- Apellis Submits New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophyhttps://modernod.com/news/apellis-announces-submission-of-nda-to-the-fda-for-pegcetacoplan-for-geographic-atrophy/2480890/Apellis Pharmaceuticals announced that the company has submitted a new drug application (NDA) to the FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Oertli Expands its Direct Distribution Networkhttps://modernod.com/news/oertli-expands-its-direct-distribution-network/2480889/Oertli Instrumente acquired the Swiss distributor Domedics AG and integrated the company as of June 1 into their global brand. Terms of the deal were not disclosed. In September 2021, Oertli Instrumente took over the majority of shares in Domedics, a Switzerland-base
- AMA: Health Insurance Industry Continues to Falter on Prior Authorization Reformhttps://modernod.com/news/ama-health-insurance-industry-continues-to-falter-on-prior-authorization-reform/2480880/Despite mounting evidence that insurer-imposed authorizations for drugs and medical services can be a hazardous and burdensome administrative obstacle to patient-centered care, the health insurer industry continues to show apathetic or ineffectual follow-through on mutually accepted reforms, acco
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 COMET-2 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-phase-3-comet-2-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2480879/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in t
- Visiox Pharma Appoints Ryan S. Bleeks as Chief Executive Officerhttps://modernod.com/news/visiox-pharma-appoints-ryan-s-bleeks-as-chief-executive-officer/2480872/Visiox Pharma announced the appointment of Ryan S. Bleeks as Chief Executive Officer. "We are excited to have Ryan join Visiox at this critical time for the organization," said Michael Derby, Visiox's Founding Investor and Executive Chairman. "His
- 2022 Bressler Prize Awarded to Dr. Sheila Nirenberg for Outstanding Accomplishments in Vision Sciencehttps://modernod.com/news/2022-bressler-prize-awarded-to-dr-sheila-nirenberg-for-outstanding-accomplishments-in-vision-science/2480866/Not-for-profit Lighthouse Guild announced today that Sheila Nirenberg, PhD, has been awarded the 2022 Bressler Prize for her outstanding advances in vision science, including deciphering the retina’s neural code which is the key to restoring meaningful vision in people who are blind fr
- Visionix and Right MFG to Enter a Long-Term Strategic Partnershiphttps://modernod.com/news/visionix-and-right-mfg-to-enter-a-long-term-strategic-partnership/2480863/Visionix, formerly Luneau Technology, and Japan-based Right MFG announced today that they have entered a long-term strategic partnership agreement with the aim of accelerating growth for both companies. Financial terms of the deal were not disclosed.
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Eyevensys Recaps Highlights from Investigator Meeting and Presentations at ARVOhttps://modernod.com/news/eyevensys-recaps-highlights-from-investigator-meeting-and-presentations-at-arvo/2480854/Eyevensys provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in its clinical trials
- MacuLogix Reaches Milestone with One Million Dark Adaptation Testshttps://modernod.com/news/maculogix-reaches-milestone-with-one-million-dark-adaptation-tests/2480853/MacuLogix announced that more than 1 million dark adaptation tests have been performed using either the company’s original AdaptDx or the head-mounted AdaptDx Pro guided by Theia. Both devices use the same proprietary technology to efficiently measure dark adaptatio